NAD+ injection feelings: separating anecdote from evidence

A recent TikTok video by Nurse Doza asks viewers what they expect to feel after an NAD+ injection. The clip implies that a predictable, often positive sensation follows administration, and that this feeling is a marker of the compound working. While such anecdotes are common, they raise a question: does the research support a consistent subjective response to NAD+?

What the clip is claiming

The video’s caption and spoken content suggest that NAD+ injections produce a recognizable set of effects—often described as a flush, warmth, or a sudden energy lift. The underlying claim is that these sensations are both expected and indicative of efficacy. However, the clip does not specify which NAD+ form is used (e.g., nicotinamide riboside, nicotinamide mononucleotide, or NAD+ itself), nor does it address the route of administration (intravenous vs. subcutaneous vs. intramuscular).

What the research neighborhood actually covers

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular respiration and energy metabolism. Preclinical studies have explored NAD+ precursors for their roles in mitochondrial function, DNA repair, and sirtuin activation. Human trials, however, are limited and focus on biomarkers rather than subjective feelings. For example, a 2019 study on nicotinamide riboside reported increased NAD+ levels in blood, but did not measure mood or energy. A 2020 trial of nicotinamide mononucleotide in older adults found improved physical performance, but again no systematic assessment of acute sensations.

Intravenous NAD+ therapy is often marketed for fatigue, addiction, and anti-aging, but peer-reviewed evidence for these uses is sparse. The FDA has not approved NAD+ for any therapeutic indication, and most clinical data come from small, short-term studies.

Limits, missing context, and what a 15-second clip cannot show

The clip omits several critical variables. First, the sensation after injection depends heavily on the formulation, dose, and infusion rate. Rapid IV administration can cause flushing, nausea, or dizziness—effects that are not necessarily therapeutic. Second, individual variability is high; some people feel nothing, while others report discomfort. Third, the placebo effect is powerful in subjective outcomes, especially when a creator’s enthusiasm sets expectations.

Moreover, the clip does not distinguish between NAD+ itself and its precursors. NAD+ is a large, charged molecule that may not cross cell membranes efficiently, whereas precursors like NR and NMN are more bioavailable. Thus, the “feeling” may be an artifact of the infusion process rather than a direct NAD+ effect.

How this maps to named research compounds

For research purposes, NAD+ is the compound in question. The catalog lists NAD+ as a standalone item, but no other NAD-related compounds (e.g., NR or NMN) are included. Therefore, any research use should focus on NAD+ itself, with careful attention to solubility, stability, and route of administration in animal models. The clip’s focus on human injection is outside typical research-use protocols, which often employ intraperitoneal or intravenous dosing in rodents.

Research-use caveat

NAD+ is sold for laboratory research only, not for human consumption. The sensations described in the clip are anecdotal and not supported by rigorous clinical evidence. Researchers should design studies that measure objective outcomes—such as NAD+ levels, mitochondrial function, or behavioral endpoints—rather than relying on subjective reports. Always follow institutional guidelines for handling and administering research peptides.

Open the full video fact-check page (transcript, takeaways, embedded clip).